The use of pegylated liposomal doxorubicin in metastatic soft tissue sarcoma
Pegylated liposomal doxorubicin demonstrated clinically relevant activity in angiosarcoma and EHE. It may be considered a therapeutic option for patients with these aggressive vascular sarcomas. Further prospective studies are warranted to confirm its efficacy and optimised treatment strategies.
Authors
- Philip Rossen
- Ninna Aggerholm‐Pedersen (ORCID: https://orcid.org/0000-0002-6859-5296)
- Hanne Rose (ORCID: https://orcid.org/0000-0002-8391-4128)
- Trang Pham (ORCID: https://orcid.org/0009-0007-4151-6467)
Institutions
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-04-23
- DOI
- https://doi.org/10.2340/1651-226x.2025.43263
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00